Nektar Therapeutics — Cash Flow (NASDAQ:NKTR) | MetaTrader

Open full chart

Financials

Overview Statement Statistics

Quarterly Annual

Cash from operating activities -313.29 M-412.66 M-304.01 M-192.61 M-175.71 M-208.51 M -208.51 M Cash from investing activities 496.21 M202.78 M365.83 M139.56 M142.57 M-1.2 M -1.2 M Cash from financing activities -80.35 M36.24 M1.51 M30 K42.12 M180.57 M 180.57 M Free cash flow -320.55 M-427.65 M-309.68 M-193.47 M-177.18 M-208.68 M -208.68 M

News

Nektar (NKTR) Moves 18.3% Higher: Will This Strength Last?

Nektar Therapeutics (NKTR) Discusses 52-Week Topline Results From REZOLVE-AA Phase 2b Extension in Severe Alopecia Areata - Slideshow (NASDAQ:NKTR) 2026-04-20

Nektar Therapeutics (NKTR) Discusses 52-Week Topline Results From REZOLVE-AA Phase 2b Extension in Severe Alopecia Areata Transcript

Nektar Therapeutics Adds To Its 129% Two-Month Run With Alopecia News

Market Feels Weak, But Stocks Tell Stories

Stay Invested In U.S. Stocks, Don't Panic Sell, Also Buy Gold

Nektar Therapeutics stock initiated with buy rating at TD Cowen

Company News for Mar 16, 2026

Oppenheimer raises Nektar Therapeutics price target to $140

Nektar Therapeutics stock hits 52-week high at 76.3 USD

Earnings call transcript: Nektar Therapeutics Q4 2025 shows cash boost and R&D expansion

Nektar Therapeutics (NKTR) Reports Q4 Loss, Tops Revenue Estimates